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In many patients with chronic renal disease, progressive loss of renal function
occurs despite absence of overt activify of the undedying disorder. The hypothesis that
tl-ris progressive renal function loss reflects a final common pathway of renal damage
was fuelled by several observations. First, by the linear renal function deterioration
that occurs in many patients irrespective diagnosis. Second, by the similarity of the
histopathology of end-stage kidneys across most renal disorders. Important evidence
was furthermore provided by the fact that risk factors for progressive long term renal
func-tion loss tend to be similar for different renal diseases. Systemic and glomerular
hypertension, glomerular protein leakage and systemic factors like hyperlipiclemia all
appear to be invoivecl, in a process that also involves mutual interactions.
Remuzzi and Bertani hypothesized a central role fbr glomerular protein
leakage in this multifàctorial process of progressive long term renal damage. They
identify rwo basic mechanisms undedying increased glomerular protein leakage. First,
an increased intraglomerular hydrostatic presstrre, and second altered permeability
characteristics of the glomerular basement rnembrane, for instance due to toxins or an
immunological reactions. In both situations the increased renal protein load is assumed
to be the mediator of the ensuing renal glomerular and interstitial damage, thus
constituting a final common pathway for the progression of renal function loss.
This placed fbcr-rs on proteinuria as a mediator of progressive renal function
loss. Cleady, this might have implications for renoprotective intervention therapy. As to
renoprotective intervention the last clecade emphasis has been on two major strategies,
i.e antihypertensive treatment and dietary protein restriction. Consiclering the alleged
role of proteinuria, it is of interest that both reduction of blood pressure ancl an
effective reduction of dietary protein intake result in a reduction of proteinuria. This is
consitent with the assllmption that recluction of proteinuria as such might be a mediator
of renoprotection, by different interventions.
Interestingly, previous investigations found ACE-inhibitors to exert a more
pronounced antiproteinuric effect than conventional antihypertensives with a similar
effect on blood pressure. Later studies showed their efficacy in providing protection
against long term renal function loss in experimental animais and in man, illustrating
their potency as a class of drugs of proven renoprotective potential. Yet renoprotection
afforded by ACE inhibition is not complete, and it would be useful to unravel
their mechanism of action, in order to gr"iide the development of more effective
r€noprotective strategies. Or.rr stuclies aimed to elucidate the mechanisms of the
antiproteinuric and renoprotective action of ACE inhibition, by studying the effects of
ACE inhibition in adriamycin-induced proteinuria in the rat.
Adriamycin-incluced proteinuria is a well-established normotensive rat model
fbr proteinuria-induced progressive renal damage. However, at the onset of our studies
its suitabiliry as a tool fbr intervention studies was sti1l disputed. Therefore, we had to
investigate ancl validate its properties as a tool for renoprotective intervention studies
(Chapters I and II). To this purpose we deliberately refrained from a common
practice in intervention studies in experimental renal disease, i.e. a study design where
intervention starts before, or at the time of disease induction. By contrast, we investigated
the properties of the model in a setting that more closely resembles the treatment




In this chapter we tested the hypothesis that in adriamycin-induced
proteinuria, like in Human renal disease, dietary sodium restriction potentiates the
effects of ACE inhibition on blood pressure and proteinuria. Sodium intake per se did
not affect blood pressure or the severity of proteinuria. The ACE-inhibitor lisinopril
reduced blood pressure as well as proteinuria. In accord with our hypothesis, these
effects were potentiated bv dietarv sodium restricíon.
Chapter tr
Adriamycin nephrosis has been used by many different laboratories. It is
induced by a single or a double dose of adriamycin with doses thatvary considerably
between investigators, from 2 to 7,5 mg/kg. Intervention studies with ACE-inhibitors in
this model have provided conflicting results. We hypothesized that these discrepancies
might be related to the dose of adriamycin used to induce proteinuria. To test this
hypothesis we compared the effects of three different doses of adriamycin (1, 2 and 3
mg/kg) on proteinuria and glomerulosclerosis and on the therapeutic efficacy of
ACE-inhibition on these parameters. \íe found that indeed the dose of adriamycin used
to induce proteinuria was crucial for the properties of the model. It appeared to be an
important determinant not only of the eventual severiry of glomerulosclerosis, but
notably also of the responsiveness to ACE-inhibition. Despite a more or less similar
proteinuria in the 3 mg/kg animals as compared to the 2 mg/kg animals, the therapy
response to ACE inhibition was markedly different, with a clearcut response in the
2 mg/kg animals, and a :u.trítally absent response in the 3 mg/kg animals. Thus, in
the interpretations of findings in this model the dose of adriamycin used should be
carefully considered. Under the experimental conditions of our laboratory in the \Tistar
rat strain (Harlan) 2 mg/kg adriamycin appeared to be the most appropriate dose. \íe
want to note, however, that the optimal dose may not necessarily be similar for different
experimental settings as the susceptibility to adriamycin toxiciry may vary across
different rat strains and depend on experimental conditions.
Chapter III
Reduction of proteinuria might play a role in the renoprotective effect of
ACE-inhibition. If so, an effective antipÍoteinuric response to AcE-inhibition would
predict subsequent protection against renal structural damage. This hypothesis was
tested in 96 male \Wistar rats with established adriamycin nephrosis. Reduction in
proteinuria was achieved by lisinopril (0, 2, 5 and 10 mg/kg/z4h) on two different
sodium intakes: normal sodium (0,3% NaCl) and restricted sodium (0,05% NaCl).
Therapy started six weeks after the induction of the disease and was continued for six
weeks. Lisinopril reduced blood pressure by 32+4"/" and proteinuia by an average of
72!770 with stabilization after two weeks. Considerable interindividual differences in
antiproteinuric response were found. Glomerulosclerosis score was significantly
reduced. Sodium restriction in itself did not affect blood pressure, proteinuria and
glomerulosclerosis score, but the effects of ACE-inhibition on blood pressure and
proteinuria were enhanced by dietary sodium restriction. Interestingly, the more
proteinuria was reduced initially in an individual rat the less sclerosis was found on the
long term. Thus, the individual short-term aníproteinuric effect predicts protection
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reduction of proteinuria is a mechanism by which AcE-inhibition exerts renoprotection.
Chapter fV
ACE-inhibition not only decreases the formation of angiotensin II, but also interferes
with the breakdown and inactivation of bradykinin. In the studies described in this
chapter we aimed to differentiate betlveen these two possible mediating pathways. Foltr
series of chronic experiments in established adriamycin nephrosis were performed. In
the first series lisinopril reduced blood pressure and proteinuria after fwo weeks of
treatment. Subsequent continuous intraperitoneal infusion of angiotensin-Il for wo weeks
partially restored proteinuria whereas blood pressure increased to almost pretreatment
levels. Subsequent withdrawal of angiotensin-Il restored the antiproteinuric effect of
lisinopril, whereas subsequent withdrawal of ACE-inhibition restored proteinuria to
pre-ACE-inhibition levels. In the second series an angiotensin-Il antagonist reducecl
blood pressure and proteinuria, similar to the effect of lisinopril. In the third series
lisinopril reducecl blood pressure and proteinuria. Subsequent intraperitoneal infusion
of a bradykinin antagonist for two weeks had no effect on blood pressure or on
proteinuria. In the fourth series a continllous two weeks infusion of exogenous
bradykinin was used to mimic decreased bradykinin breakdown. This had no effect on
proteinuria but did induce a fall in blood pressure. The blood pressure lowering effect
of exogenous infused bradykinin was completely reversed by one week of bradykinin
antagonist infusion while proteinuria remained unchanged. Thus, the antlproteinuric
effect of ACE-inhibition appears to be independent of bradykinin effects in this model,
supporting a main role for reduction of angiotensin-Il in the antiproteinuric action of
ACE-inhibition.
ChapterV
This chapter explores one of the possible mechanisms of the antiproteinuric effect of
ACE-inhibition. Reduction of systemic and intraglomerular pressnre have been statecl to
be involved in the antiproteinuric effect. However, at the onset of ACE-inhibition all
hemodynamic efïects are immediately apparent whereas the antiproteinuric effect has a
more gradual onset of action. This suggests involvement of additional factors such as
renal structural alterations improving the glomerular permselectivity. Heparan-sulfate
proteoglycans play a crucial role in the permselective properties of the glomerular
basement membrane. 'Jíe therefore investigatecl the effects of ACE inhibition on
proteinuria, focal glomerulosclerosis and heparan-sulfate proteoglycan staining in
adriamycin nephrosis. Adriamycin nephrosis was associated with impairment of
heparan-sulfate side-chain staining preceding focal glomerulosclerosis. \ilhen focal
glomerulosclerosis ensued, both heparan-sulfate side-chain and heparan-sulfate
proteoglycan core-staining were impaired. Interestingly, this impairment was
significantly less severe in the lisin-opril treated rats. The latter finding is consistent
with the assllmption that structural effects on the glomerular basement membrane
contribute to the renoprotective effects of ACE-inhibition in this moclel.
101
ChapterVI
In contrast to the previous chapters in this last chapter we return to the clinical
setting, reviewing the predictive value of the short term antiproteinuric effect of
ACE-inhibition for subsequent renoprotective efficacy in patients with non-diabetic
renal disease. The reviewed studies demonstrate that a more effective early reduction of
proteinuria consistently predicts a more favorable course of long term renal function
during therapy. This relationship is apparent for between-group studies comparing the
renoprotective efficacy of different therapeuíc regimens as well as for within-group
comparisons for patients on a single regimen. This relationship shows a remarkable
paraliel with the evidence for a better renal prognosis after spontaneous remission of
proteinuria. Taken together these findings support the assumption that proteinuria
might be a mediator of long term renal function loss. As to the mechanism by which
ACE-inhibitors afford long term renoprotection the predictive value of the short term
reduction in proteinuria, as opposed to the lack of a predictive value of the blood
pressure response, supports the assumption that specific renal effects are involved in
long term renoprotection. The findings reviewed suggest that the investigation of
treatment regimens aimed at aggressive reduction of proteinuria might provide a
strategy to further enhance the potency of long term renoprotection.
For the moment, despite the advancements of the last decade, proteinuric renal
disease is still essentially a progressive condiíon with a grim long term prognosis for
most patients. If titration for reduction of proteinuria could further ameliorate long term
GFR decline, this would not only provide evidence for proteinuria as a mediator of renal
damage, it might also improve the outlook for the patient with chronic renal failure.
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